Search Videos by Topic or Participant
Browse by Series:

Novel Treatment Approaches to Relapsed/Refractory CLL

Panelists: Myron S. Czuczman, MD, Roswell Park; John C. Byrd, MD, Ohio State;Richard Furman, MD, Weill Cornell; Thomas J. Kipps, MD, UCSD; Shuo
Published: Monday, Mar 09, 2015
For High-Definition, Click
FDA approvals for ibrutinib and idelalisib have made discussions about treating relapsed/refractory chronic lymphocytic leukemia (CLL) less complicated, explains John C. Byrd, MD. There are several regimens available in the second-line setting for patients with CLL; however, ibrutinib and idelalisib have been shown to be more effective. The next step in optimizing treatment in this setting will be combination strategies, suggests Myron S. Czuczman, MD.

Early data have shown that complete remission rates in patients treated with ibrutinib and rituximab are not very different from that seen in patients treated with ibrutinib alone, Thomas J. Kipps, MD, notes. In addition, the possibilities of severe adverse events with some combinations must be examined before they are recommended. There are several factors to consider, such as the benefit of combinations versus risk coupled with costs and duration of use, when contemplating treatment regimens in relapsed/refractory CLL.
Slider Left
Slider Right
For High-Definition, Click
FDA approvals for ibrutinib and idelalisib have made discussions about treating relapsed/refractory chronic lymphocytic leukemia (CLL) less complicated, explains John C. Byrd, MD. There are several regimens available in the second-line setting for patients with CLL; however, ibrutinib and idelalisib have been shown to be more effective. The next step in optimizing treatment in this setting will be combination strategies, suggests Myron S. Czuczman, MD.

Early data have shown that complete remission rates in patients treated with ibrutinib and rituximab are not very different from that seen in patients treated with ibrutinib alone, Thomas J. Kipps, MD, notes. In addition, the possibilities of severe adverse events with some combinations must be examined before they are recommended. There are several factors to consider, such as the benefit of combinations versus risk coupled with costs and duration of use, when contemplating treatment regimens in relapsed/refractory CLL.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x